JP2005512962A - 抗ｐｄｇｆ抗体および設計抗体の産生方法 - Google Patents

抗ｐｄｇｆ抗体および設計抗体の産生方法 Download PDF

Info

Publication number
JP2005512962A
JP2005512962A JP2003528864A JP2003528864A JP2005512962A JP 2005512962 A JP2005512962 A JP 2005512962A JP 2003528864 A JP2003528864 A JP 2003528864A JP 2003528864 A JP2003528864 A JP 2003528864A JP 2005512962 A JP2005512962 A JP 2005512962A
Authority
JP
Japan
Prior art keywords
antibody
sequence
designed
library
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003528864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512962A5 (https=
Inventor
キャサリン エス． ボウディッシュ，
シャナ フレデリックソン，
アンキ クレッズ−ロメル，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2005512962A publication Critical patent/JP2005512962A/ja
Publication of JP2005512962A5 publication Critical patent/JP2005512962A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2003528864A 2001-09-20 2002-09-20 抗ｐｄｇｆ抗体および設計抗体の産生方法 Withdrawn JP2005512962A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32353701P 2001-09-20 2001-09-20
US32354401P 2001-09-20 2001-09-20
US37999402P 2002-05-13 2002-05-13
PCT/US2002/030086 WO2003025019A1 (en) 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies

Publications (2)

Publication Number Publication Date
JP2005512962A true JP2005512962A (ja) 2005-05-12
JP2005512962A5 JP2005512962A5 (https=) 2005-12-22

Family

ID=27406282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003528864A Withdrawn JP2005512962A (ja) 2001-09-20 2002-09-20 抗ｐｄｇｆ抗体および設計抗体の産生方法

Country Status (4)

Country Link
EP (1) EP1436329A4 (https=)
JP (1) JP2005512962A (https=)
CA (1) CA2460587A1 (https=)
WO (1) WO2003025019A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511706A (ja) * 2001-12-03 2005-04-28 アレクシオン ファーマシューティカルズ， インコーポレイテッド ハイブリッド抗体
JP2015522576A (ja) * 2012-06-28 2015-08-06 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 血小板由来成長因子に結合する設計アンキリンリピートタンパク質
JP2019006732A (ja) * 2017-06-27 2019-01-17 学校法人東京理科大学 Ｍｙｃタンパク質阻害剤、Ｍｙｃタンパク質阻害方法、抗神経芽腫剤及びＭｙｃタンパク質の過剰発現を伴う疾患の治療方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
US20040009178A1 (en) * 2002-02-11 2004-01-15 Bowdish Katherine S. Immunotherapeutics for biodefense
JP2007525458A (ja) * 2003-04-23 2007-09-06 メダレックス インコーポレイテッド インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
EP1737890A2 (en) * 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2009129538A2 (en) * 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
NZ629697A (en) 2012-03-15 2017-01-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
RU2676102C2 (ru) 2012-09-27 2018-12-26 Аллерган, Инк. Биодеградируемые системы доставки лекарственных средств для долговременного высвобождения белков
JP6649246B2 (ja) 2013-03-14 2020-02-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法
DK4374873T3 (da) 2013-07-12 2025-11-03 Astellas Us Llc Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
WO1999024059A1 (en) * 1997-11-07 1999-05-20 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
DK1034298T3 (da) * 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511706A (ja) * 2001-12-03 2005-04-28 アレクシオン ファーマシューティカルズ， インコーポレイテッド ハイブリッド抗体
JP2015522576A (ja) * 2012-06-28 2015-08-06 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 血小板由来成長因子に結合する設計アンキリンリピートタンパク質
JP2019006732A (ja) * 2017-06-27 2019-01-17 学校法人東京理科大学 Ｍｙｃタンパク質阻害剤、Ｍｙｃタンパク質阻害方法、抗神経芽腫剤及びＭｙｃタンパク質の過剰発現を伴う疾患の治療方法

Also Published As

Publication number Publication date
EP1436329A4 (en) 2005-04-27
WO2003025019A1 (en) 2003-03-27
CA2460587A1 (en) 2003-03-27
EP1436329A1 (en) 2004-07-14
WO2003025019A9 (en) 2004-05-06
WO2003025019A8 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
US20030219839A1 (en) Anti-PDGF antibodies and methods for producing engineered antibodies
JP2005512962A (ja) 抗ｐｄｇｆ抗体および設計抗体の産生方法
JP6678627B2 (ja) 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
JP5685274B2 (ja) 結合タンパク質の混合物
JP6216940B2 (ja) ラクダ科動物由来の抗原結合ポリペプチド
JP2015524404A (ja) 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体
CN112646032B (zh) 靶向bcma的具有人猴交叉的人源化单克隆抗体
CN102076714A (zh) 结合Aβ(1-42)球聚体的人源化抗体及其应用
JP7624478B2 (ja) 癌治療において壊死を標的とするヒト化抗核抗体
AU2004261980A1 (en) Antibody CDR polypeptide sequences with restricted diversity
WO2001031065A1 (en) Humanization of non-human, mammalian antibodies
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
JP2005532825A (ja) ベネズエラウマ脳炎ウイルスに対するヒト化抗体
US20150218287A1 (en) Tumor selective antibodies specific to oncofetal antigen/immature laminin receptor protein
JP2026509245A (ja) 抗体およびその使用
Padoa et al. Engineered antibodies: A new tool for use in diabetes research
CN111201239A (zh) 用于开发特异于表位翻译后修饰状态的抗体的方法和组合物
AU2002341785A1 (en) Anti-PDGF antibodies and methods for producing engineered antibodies
CN115244079B (zh) 结合人ngf的抗体、其制备方法和用途
EP4482860A1 (en) Human-like target-binding proteins
Putelli Human antibody phage technology-isolation and characterization of monoclonal antibodies for the targeting of cancer and rheumatoid arthritis
HK1201280B (en) Anti-vegf antibody
HK1201280A1 (en) Anti-vegf antibody

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060110